Pranlu Powder for Suspension

Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.

Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

Adult: 225 mg bid.
Child: 3.5 mg/kg bid. Max dose: 10 mg/kg/day (not exceeding 450 mg daily).

Concurrent use with warfarin and other anticoagulants may cause an increase in prothrombin time.

Acute asthma attacks; hepatic impairment/cirrhosis.

Headache, increased incidence of resp tract infection, GI disturbances, induced generalised pain, fever, myalgia, arthralgia.

Renal impairment. Possible elevations in liver enzymes. Withdraw treatment in patients showing signs consistent with Churg-Strauss syndrome.